NDAORALTABLET
Approved
Mar 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NAQUIVAL is a fixed-dose combination oral tablet containing reserpine (an alkaloid antihypertensive) and trichlormethiazide (a thiazide diuretic), approved in 1960 for hypertension management. This synergistic combination addresses blood pressure control through dual mechanisms: reserpine depletes catecholamine stores while trichlormethiazide promotes sodium and water excretion. The product represents a legacy antihypertensive from the pre-ACE inhibitor era.
LOE Approaching
This product is in terminal lifecycle with minimal commercial support; career opportunities are limited to legacy maintenance roles with small teams focused on compliance and pharmacovigilance.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NAQUIVAL offers minimal career advancement; the product is in terminal decline with zero linked job openings and a focus on regulatory maintenance rather than commercial growth or innovation. This role is suitable only for professionals seeking stable, low-pressure legacy product stewardship or those near retirement.
Regulatory Affairs SpecialistPharmacovigilance Associate
Worked on NAQUIVAL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.